The cardiac biomarkers market comprises products that help in the detection of cardiac dysfunction and injuries. Cardiac biomarkers include troponin, CK-MB, myoglobin, Ischemia Modified Albumin (IMA), and others that assist physicians in diagnosing conditions associated with heart attacks, cardiomyopathy, myocarditis, and other cardiovascular diseases. The cardiac biomarkers testing is non-invasive, easy to perform, and provides quick and reliable results. The rising burden of cardiovascular diseases due to unhealthy lifestyle choices such as smoking, alcohol consumption, lack of physical activity along with increasing geriatric population are major factors augmenting the demand for cardiac biomarkers.

The Global Cardiac Biomarkers Market is estimated to be valued at US$ 11331.71 Mn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in the Cardiac Biomarkers are Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Randox Laboratories Ltd., Siemens Healthineers, and BioMérieux SA.
The growing prevalence of cardiovascular diseases and rising geriatric population are major factors augmenting the demand for cardiac biomarkers globally. As per WHO estimates, cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year.
Technological advancements in Cardiac Biomarker Market Size testing with rapid diagnostic platforms, high sensitivity & specificity cardiac biomarker assays are expected to witness high growth over the forecast period. POC testing platforms are gaining popularity for cardiac biomarker testing for quick diagnosis in hospitals and diagnostic centers.

Fastest Growing Region for Cardiac Biomarkers Market
The Asia Pacific region is poised to be the fastest growing market for cardiac biomarkers globally during the forecast period. This is due to improving healthcare infrastructure, increasing medical tourism, rising awareness regarding cardiac diagnostics and expanding patient pool of cardiac disorders like hypertension, diabetes in developing countries. Additionally, growing geriatric population prone to cardiac ailments, favorable government initiatives and presence of emerging economies with huge patient pools offer significant growth opportunities. However, lack of proper regulatory guidelines and limited awareness continue to challenge the regional market to realize its full potential.

Get more insights on Cardiac Biomarkers Market